RISS 검색 - 국내학술지논문 상세보기

다국어 초록 (Multilingual Abstract)

Background/Aims: Prognostic models are lacking for patients with recurrent hepatocellular carcinoma (HCC) following surgical resection. This study devised and validated a new hepatoma arterial-embolization prognostic (HAP) score optimized for use in patients undergoing treatment with transarterial chemoembolization (TACE) for recurrence subsequent to surgical resection of HCC. Methods: Training cohort (n=424) and validation cohort (n=350) patients with recurrent HCC after resection treated with TACE between 2003 and 2016 were enrolled. Cox regression and area under the receiver operating characteristic curve (AUC) analyses were used to identify risk factors for survival and to calculate the predictive performance of risk scores, respectively. Results: The median age of the study population was 59.2 years. α-Fetoprotein >400 ng/mL (hazard ratio [HR]=1.815), serum albumin ≤3.5 g/dL (HR=1.966), tumor number ≥2 (HR=1.425), tumor size >5 cm at resection or recurrence (HR=1.356), segmental portal vein invasion at resection or recurrence (HR=2.032), and time from resection to recurrence ≤1 years (HR=1.849) independently predicted survival (all p<0.05). The postoperative HAP (pHAP) model based on the rounded HRs of these variables showed an AUC of 0.723 for predicting survival at 3 years, which was significantly higher than AUCs of other HAP-based models, including HAP, modified HAP, and modified HAP-II scores (0.578-0.621) (all p<0.05). The accuracy of pHAP was maintained in the entire cohort (n=774; AUC=0.776 at 3 years). Conclusions: A new pHAP score optimized for patients treated with TACE due to recurrent HCC after resection showed acceptable accuracy and was externally validated. Further studies of means by which to select treatment options other than TACE for high-risk patients according to pHAP scores are warranted.

참고문헌 (Reference)

1 Pinato DJ, "Validation of the hepatoma arterial embolization prognostic score in European and Asian populations and proposed modification" 13 : 1204-1208, 2015

2 Forner A, "Treatment of intermediate-stage hepatocellular carcinoma" 11 : 525-535, 2014

3 Marelli L, "Transarterial therapy for hepatocellular carcinoma : which technique is more effective? A systematic review of cohort and randomized studies" 30 : 6-25, 2007

4 김준영, "Transarterial chemoembolization versus resection for the intermediate stage hepatocellular carcinoma" 대한간학회 22 (22): 250-258, 2016

5 Zhao Y, "Transarterial chemoembolization in hepatocellular carcinoma with vascular invasion or extrahepatic metastasis : a systematic review" 9 : 357-364, 2013

6 Luo J, "Transarterial chemoembolization for unresectable hepatocellular carcinoma with portal vein tumor thrombosis : a prospective comparative study" 18 : 413-420, 2011

7 Sieghart W, "The ART of decision making : retreatment with transarterial chemoembolization in patients with hepatocellular carcinoma" 57 : 2261-2273, 2013

8 이정민, "Survival outcomes of hepatic resection compared with transarterial chemoembolization or sorafenib for hepatocellular carcinoma with portal vein tumor thrombosis" 대한간학회 22 (22): 160-167, 2016

9 Kim BK, "Risk prediction for patients with hepatocellular carcinoma undergoing chemoembolization : development of a prediction model" 36 : 92-99, 2016

10 Tung-Ping Poon R, "Risk factors, prevention, and management of postoperative recurrence after resection of hepatocellular carcinoma" 232 : 10-24, 2000